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Unraveling the Mysteries of IGF-1 
Signaling in Melanoma
John	T.	Lee1,	Patricia	Brafford1	and	Meenhard	Herlyn1
The inherent ability of a cell to undergo apoptosis governs a number of develop-
mental processes essential to proper mammalian development. Into adulthood, 
the pathways that potentiate the apoptotic response are extremely diverse and 
finely regulated to prevent potential diseases. Of these, cancer is often associated 
with loss of an apoptotic response. Hanahan and Weinberg (2000) list evasion of 
apoptosis as a hallmark feature acquired during neoplastic transformation. The 
impact of this event is dramatic on several levels; avoidance of apoptosis not only 
prevents programmed cell death in an array of cell types but also promotes chemo-
therapeutic resistance during anticancer regimens.
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In	 mammalian	 systems,	 there	 are	 cur-
rently	12	known	members	of	 the	Bcl-2	
family	of	apoptotic	regulators	(Youle	and	
Strasser,	2008);	this	group	is	divided	into	
anti-apoptotic	 members	 (Bcl-2,	 Bcl-XL,	
Mcl-1,	 etc.)	 and	pro-apoptotic	proteins	
(BID,	 BAX,	 BAD,	 NOXA,	 etc.).	 A	 deli-
cate	 balance	 of	 these	 proteins	 dictates	
the	fate	of	a	given	cell;	a	rheostat	exists	
between	 pro-	 and	 anti-apoptotic	 Bcl-2	
family	members	to	modulate	cell	death	
or	survival,	whereby	whichever	is	more	
highly	expressed	determines	the	cellular	
outcome	 (Oltvai	 et al.,	 1993).	 Survivin	
(encoded	by	BIRC5)	is	a	member	of	the	
inhibitors	of	apoptosis	family	of	proteins	
and	functions	similarly	to	anti-apoptotic	
Bcl-2	 family	 members	 (Altieri,	 2008).	
Collectively,	 these	 apoptotic	 proteins	
control	 fundamental	 cell	 fate	decisions	
that	 underlie	 the	 difference	 between	
homeostasis	and	onset	of	disease.
Metastatic	 melanoma	 is	 a	 complex	
malignancy	 that	 is	 refractory	 to	 nearly	
all	known	chemotherapeutics;	as	a	result	
of	the	relative	dearth	of	available	thera-
pies,	the	5-year	survival	rate	for	patients	
afflicted	 with	 metastatic	 melanoma	 is	
approximately	 15%.	The	 inherent	 drug	
resistance	observed	in	melanoma	may	be	
due,	in	part,	to	the	network	of	signaling	
pathways	that	are	activated	during	malig-
nant	 transformation	 (Bennett,	 2008).	
Although	the	cooperative	phenotype	that	
results	from	activation	of	these	pathways	
is	 similar,	 their	 individual	 contributions	
and	overall	 significance	 to	disease	may	
greatly	contrast;	thus,	it	is	paramount	to	
understand	how	each	pathway	can	con-
tribute	to	disease	initiation,	progression,	
and	clinical	manifestation.
The	 IGF-1	 signaling	 axis	 originates	
from	 the	 IGF-1	 receptor.	 IGF-1R	 is	 a	
heterotetramer	 consisting	 of	 two	 extra-
cellular	α	 subunits	 and	 two	β	 subunits	
that	 encompass	 the	 transmembrane	
and	tyrosine	kinase	domains	(Hartog	et 
al.,	2007).	After	ligand	binding,	IGF-1R	
initiates	a	series	of	signaling	events	that	
positively	 affect	 the	 mitogen-activated	
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protein	 kinase	 and	 phosphatidylinosi-
tol-3-kinase	 pathways,	 among	 others.	
Because	these	pathways	are	commonly	
activated	in	a	variety	of	cancers,	it	is	not	
surprising	that	a	number	of	monoclonal	
antibodies	 and	 small-molecule	 inhibi-
tors	 of	 IGF-1R	 are	 currently	 in	 clinical	
development	(Hartog	et al.,	2007).
Somewhat	 surprisingly,	 IGF-1	 is	 not	
expressed	in	melanoma	cells	(Rodeck	et 
al.,	1991);	however,	 IGF-1R	expression	
is	correlated	with	melanoma	progression	
(Kanter-Lewensohn	et al.,	 2000).	These	
observations	 suggest	 that	 paracrine-
derived	 signals	may	 be	 responsible	 for	
activation	 of	 IGF-1R	 during	 advance-
ment	 of	 melanocytic	 disease.	 Indeed,	
our	laboratory	previously	demonstrated	
that	 fibroblast-derived	 IGF-1	 promotes	
growth	and	survival	of	early-stage	mela-
noma	cells	(Satyamoorthy	et al.,	2001).	
In	this	issue,	Hilmi	et al.	 (2008)	bolster	
a	 role	 for	 IGF-1	 in	 melanoma	 patho-
physiology	 by	 revealing	 that	 resistance	
to	apoptosis	 in	melanoma	may	be	due	
to	 IGF-1-mediated	 expression	 of	 the	
anti-apoptotic	 proteins	 Bcl-2,	 Bcl-XL,	
and	 survivin	 (Hilmi	 et al.,	 2008).	 The	
results	 from	 this	 study	 shed	 additional	
light	on	the	mechanisms	by	which	micro-
environmental	 influences	 promote	 the	
chemoresistant	 phenotype	 associated	
with	most	advanced-stage	melanomas.
Using	 two	 melanoma	 cell	 lines	
(MeWo	and	A375),	the	authors	demon-
strated	that	IGF-1	is	sufficient	to	inhibit	
tumor-necrosis-factor-related	 apoptosis-
inducing	 ligand	 (TRAIL)-induced	 apop-
tosis;	 this	 antagonistic	 effect	 appeared	
to	 bypass	 caspase-8	 activation	 and,	
instead,	 was	 dependent	 on	 caspases-9	
and	-3.	This	latter	observation	is	intrigu-
ing	because	TRAIL	 is	generally	 thought	
to	 induce	 apoptosis	 through	 a	 binding	
event	with	an	appropriate	death	recep-
tor,	 thereby	 initiating	 the	 “extrinsic”	
apoptotic	pathway	characterized	by	cas-
pase-8	activation;	here,	caspases-3	and	
-9	were	activated	rather	than	caspase-8.	
These	caspases	(9	and	3)	are	associated	
with	the	“intrinsic”	pathway	that	is	affili-
ated	 with	 compromised	 mitochondrial	
function.	 Experiments	 measuring	 mito-
chondrial	membrane	potential	validated	
those	 data	 and	 supported	 the	 prem-
ise	 that	 IGF-1	 rescues	 TRAIL-induced	
apoptosis	via	prevention	of	the	intrinsic	
apoptotic	 signaling	 cascade.	 Finally,	
upregulation	 of	 the	 anti-apoptotic	 pro-
teins	 Bcl-2,	 Bcl-XL,	 and	 survivin	 was	
provided	 as	 the	 mechanistic	 evidence	
for	the	biological	effects	of	IGF-1.
Previous	 studies	 have	 demonstrated	
a	 role	 for	 IGF-1	 in	 the	 proliferation	 of	
early-stage	 melanoma	 cells	 but	 not	
metastatic	 melanomas	 (Satyamoorthy	
et al.,	2001),	 suggesting	 that	 IGF-1	has	
little	 effect	 on	 melanoma	 growth	 after	
the	 radial-growth	 phase	 of	 disease;	
this	 new	 report	 assigns	 a	 novel	 role	 to	
IGF-1	 during	 disease	 progression:	
evasion	 of	 apoptosis.	 The	 malignant	
phenotype	 of	melanoma	 is	 undeniably	
resistant	 to	an	assortment	of	anticancer	
therapeutics.	 The	 mechanisms	 respon-
sible	 for	 drug	 resistance	 in	 melanoma	
are	likely	not	limited	to	a	single	pathway	
or	 effector;	 instead,	 the	 chemoresistant	
nature	 of	 melanomas	 is	 probably	 the	
additive	result	of	a	number	of	drug	efflux	
pumps,	activation	of	cell	 survival	path-
ways,	and,	potentially,	the	presence	of	a	
slow-cycling	tumor-initiating	cell	popu-
lation.	The	 IGF-1	 growth	 factor	 is	 now	
described	as	another	potential	mediator	
of	 cell	 survival	 in	 melanoma,	 thereby	
implicating	IGF-1	signaling	in	additional	
biomolecular	 processes	 essential	 for	
maintenance	of	disease.
The	 precise	 cell	 type	 that	 produces	
IGF-1	in	the	tumor	microenvironment	is	
still	uncertain.	It	is	apparent	that	mela-
noma	cells	themselves	express	minimal	
amounts	 of	 IGF-1,	 indicating	 that	 the	
presence	 of	 IGF-1	 is	 from	 a	 paracrine	
source.	Others	have	suggested	that	stro-
mal	 components	 are	 responsible	 for	
IGF-1	production	in	other	cancer	lesions	
(Cullen	et al.,	1991;	van	der	Laan	et al.,	
1995),	and	melanoma	appears	to	be	no	
different.	Our	 laboratory	 has	 extensive	
gene	expression	data	 for	a	 large	panel	
of	melanoma	cell	lines;	Figure	1	depicts	
the	 expression	 profiles	 of	 the	 target	
genes	of	IGF-1	signaling	(Bcl-2,	Bcl-XL,	
and	survivin),	as	described	by	Hilmi	et 
al.	Our	data	suggest	that	the	expression	
of	 these	 survival	 factors	 varies	 greatly	
across	melanoma	 samples,	 rather	 than	
|IGF-1	may	mediate	expression	of	anti-apoptotic	proteins.
Figure 1. expression profiling of Bcl-2, Bcl-XL, and survivin in a panel of melanoma cell lines. Gene	
transcription	profiling	of	30	melanoma	cell	lines	was	performed	using	Affymetrix	U133A	microarrays.	
An	absolute	expression	analysis	was	performed	using	Affymetrix	MAS	5.0	and	the	data	were	normalized	
per	gene	in	GeneSpring	GX	7.3.1.	The	target	genes	Bcl-2,	Bcl-XL	(BCL2L2),	and	survivin	(BIRC5)	were	
visualized	using	supervised	clustering	analysis.	The	color	bar	indicates	the	fold	expression	level	from	the	
normalized	value	of	1	(yellow).	Red	indicates	high	expression	and	blue	indicates	decreased	expression	
compared	with	the	normalized	value	per	gene.
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being	 highly	 expressed;	 the	 apparent	
discrepancy	between	our	data	and	those	
reported	by	Hilmi	et al.	may	be	due	to	
one	of	several	factors.	First,	the	authors	
used	 only	 two	 cell	 lines	 in	 their	 stud-
ies,	which	might	have	not	been	enough	
lines	 to	 accurately	 predict	 a	 similar	
association	across	a	larger	sample	size.	
Next,	our	gene	expression	profiling	was	
performed	in	the	continued	presence	of	
excess	 (5	µg/ml)	 insulin,	 rather	 than	 a	
transient	treatment	with	IGF-1	to	serum-
starved	 cells;	 this	 minor	 experimental	
difference	 could	 account	 for	 the	 dis-
crepancy	between	the	two	sets	of	data.
Although	 the	 results	 of	 Hilmi	 et al.	
(2008)	help	to	establish	a	role	for	IGF-1	
signaling	in	expression	of	anti-apoptotic	
molecules,	 they	 leave	 other	 questions	
unanswered.	 For	 example,	 what	 are	
the	 molecular	 mechanisms	 by	 which	
IGF-1	 is	 able	 to	 induce	 expression	 of	
Bcl-2,	 Bcl-XL,	 and	 survivin—are	 these	
proteins	coregulated	or	similarly	affected	
by	distinct	downstream	mediators	of	the	
IGF-1	 signaling	 axis?	 Likewise,	MeWo	
and	 A375	 cells	 represent	 metastatic	
melanomas—is	 the	 prosurvival	 pheno-
type	 after	 IGF-1	 treatment	 a	 function	
of	 disease	 stage	 or	 is	 this	 observation	
merely	coincidental?	Furthermore,	does	
inhibition	of	IGF-1	signaling	(via	IGF-1R	
monoclonal	 antibodies,	 for	 example)	
synergize	with	 traditional	 chemothera-
peutics	 to	 initiate	 disease	 regression?	
These	 types	 of	 studies	 appear	 promis-
ing	in	preclinical	investigations	(Ji	et al.,	
2007;	 Maloney	 et al.,	 2003),	 whereas	
results	 from	 early	 clinical	 trials	 are	
still	pending.
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First-Class Delivery: Getting Growth 
Factors to Their Destination
Jeffrey	M.	Davidson1
Growth factor bioavailability in therapeutic applications such as wound healing 
is limited by extracellular matrix sequestration, proteolysis, and clearance. Local, 
transient delivery by gene transfer is an attractive concept. Many transfection 
strategies are available, and adenoviral vectors are in clinical trials. Keratinocyte 
growth factor-1 (KGF-1), an epithelial-specific member of the fibroblast growth 
factor (FGF) family, has achieved limited success in protein formulations. Matrix- 
and cell-based strategies for delivering a KGF-1 virion to target tissue may 
improve the reproducibility and efficiency of the process, although the advantag-
es of cell-based therapy must be weighed against its added cost and complexity.
Journal of Investigative Dermatology (2008),	128,	1360–1362.	doi:10.1038/jid.2008.128
Despite	 two	 decades	 of	 advancement	
in	the	understanding	and	use	of	growth	
factors	 for	 wound	 healing,	 there	 has	
been	limited	clinical	success	(Leahy	and	
Lawrence,	2007;	Papanas	and	Maltezos,	
2007).	Numerous	strategies	for	transient	
gene	delivery	of	growth	factor	cDNA,	by	
driving	 sustained,	 local	 overexpression	
of	the	factor,	appear	to	overcome	obsta-
cles	to	delivery	of	and	response	to	these	
proteins	 in	 the	 hostile	wound	 environ-
ment	(Eming et al.,	2007).	Transient	gene	
delivery	avoids	many	of	 the	challenges	
of	 stable	 transformation	needed	 to	cor-
rect	 genetic	 defects.	 Among	 the	 many	
potential	 approaches	 for	DNA	 transfer,	
early	 clinical	 findings	 with	 adenoviral	
recombinant	 platelet-derived	 growth	
factor-BB	 (PDGF-BB)	 therapy	 have	
been	 promising.	 Using	 a	 humanized	
mouse	model,	Escámez	et	al.	(2008,	this	
issue)	 have	 compared	 several	methods	
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